Key result
Multicenter study protocol evaluates plasma sCLEC-2 utility in 600 AIS and TIA patients.
Cohort (n=600)
Yes
Answers are grounded in this paper and cite their sources.
Reports protocol evaluating sCLEC-2 in acute ischaemic stroke and TIA, indicating potential utility for stroke subtype differentiation.
Introduction Soluble C-type lectin-like receptor 2 (sCLEC-2) is a new biomarker for platelet activation, which can be easily measured by usual blood collection. We conducted the CLECSTRO, a prospective, observational cohort study, to evaluate the clinical implications of sCLEC-2 in patients with acute ischaemic stroke (AIS) and transient ischaemic attack (TIA). Methods and analysis The participants are patients with AIS/TIA and control patients required for differentiation from AIS/TIA. The target population is 600, including the patients and controls, who would be recruited from eight stroke centres across Japan. The inclusion criteria are AIS within 24 hours of onset and a modified Rankin Scale (mRS) score of 0–2, TIA within 7 days of onset, and contemporary patients required for differentiation from AIS/TIA. Plasma sCLEC-2 will be measured by high-sensitive chemiluminescent enzyme immunoassay using residual blood samples from routine laboratory examinations at the first visit in all patients and 7 days later or at discharge in patients with AIS/TIA. The outcomes include plasma levels of sCLEC-2 in patients with AIS/TIA and controls, sCLEC-2/D-dimer ratio in non-cardioembolic and cardioembolic AIS/TIA, correlation of sCLEC-2 with recurrence or worsening of stroke, severity of stroke, infarct size, ABCD 2 score in TIA and outcome (mRS) at 7 days and 3 months. Ethics and dissemination This study was approved by the Ethical Committee of the University of Yamanashi as the central ethical committee in agreement with the ethical committees of all collaborative stroke centres. Informed consent will be obtained by an opt-out form from the patients at each stroke centre according to the Ethical Guidelines for Medical and Biological Research Involving Human Subjects by the Japanese Ministry of Health, Labour and Welfare. Trial registration numbers NCT05579405 , UMIN000048954
No takes yet. Share an insight, caveat, or question.
Uchiyama et al. (2023) conducted a cohort in Acute ischaemic stroke (AIS) and transient ischaemic attack (TIA) (n=600). Soluble C-type lectin-like receptor 2 (sCLEC-2) plasma measurement vs. Contemporary control patients required for differentiation from AIS/TIA was evaluated on Plasma levels of sCLEC-2, sCLEC-2/D-dimer ratio, correlation with stroke recurrence/worsening, severity, infarct size, ABCD2 score, and mRS at 7 days and 3 months. Plasma sCLEC-2 will be evaluated in 600 AIS/TIA patients and controls across 8 centers in this study protocol, with no clinical results yet reported.
Synapse has enriched 10 related papers. Consider them for comparative context: